- Home
- NNN vs ROIV Comparison
NNN vs ROIV Comparison
Compare NNN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NNN | ROIV |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NNN | ROIV |
|---|---|---|
| Price | $39.74 | $21.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $43.33 | $24.31 |
| AVG Volume (30 Days) | 1.6M | ★ 8.2M |
| Earning Date | 02-10-2026 | 02-09-2026 |
| Dividend Yield | ★ 6.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $906,297,000.00 | $20,329,000.00 |
| Revenue This Year | $6.04 | N/A |
| Revenue Next Year | $4.82 | $741.42 |
| P/E Ratio | $19.15 | ★ N/A |
| Revenue Growth | ★ 4.53 | N/A |
| 52 Week Low | $35.80 | $8.73 |
| 52 Week High | $44.23 | $23.47 |
Technical Indicators
Market Signals| Indicator | NNN | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 53.08 |
| Support Level | $38.90 | $21.36 |
| Resistance Level | $39.58 | $22.72 |
| Average True Range (ATR) | 0.50 | 0.80 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 36.36 | 45.71 |
Price Performance
Historical ComparisonAbout NNN NNN REIT Inc.
NNN REIT Inc is a real estate investment trust that invests in and develops properties throughout the United States. The company generates revenue from leasing properties to tenants, including convenience stores, automotive services, fitness centers, theatres, restaurants, and banks. Rents from convenience stores and restaurants contribute the majority proportion of total revenue. The maximum of the company's properties are located in the South and Southeast of the United States.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.